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Abstract 
Background: The rise of antimicrobial use in the twentieth century has significantly reduced morbidity due to infec-
tion, however it has also brought with it the rise of increasing resistance. Some patients are on prolonged, if not “life-
long” course of antibiotics. The reasons for this are varied, and include non-infectious indications. We aimed to study 
the characteristics of this potential source of antibiotic resistance, by exploring the antibiotic dispensing practices and 
describing the population of patients on long-term antibiotic therapy.
Methods: A retrospective cross-sectional study of antibiotic dispensing records was performed at a large university 
hospital-based healthcare network in Melbourne, Australia. Outpatient prescriptions were extracted from the hospital 
pharmacy database over a 6 month period in 2014. Medical records of these patients were reviewed to determine 
the indication for prescription, including microbiology, the intended duration, and the prescribing unit. A descriptive 
analysis was performed on this data.
Results: 66,127 dispensing episodes were reviewed. 202 patients were found to have been prescribed 1 or more 
antibiotics with an intended duration of 1 year or longer. 69/202 (34%) of these patients were prescribed prolonged 
antibiotics for primary prophylaxis in the setting of immunosuppression. 43/202 (21%) patients were prescribed 
long-term suppressive antibiotics for infections of thought incurable (e.g. vascular graft infections), and 34/43 (79%) 
were prescribed by Infectious Diseases doctors. 66/202 (33%) patients with cystic fibrosis were prescribed prolonged 
courses of macrolides or fluoroquinolones, by respiratory physicians. There was great heterogeneity noted in indica-
tions for prolonged antibiotic courses, as well as antibiotic agents utilised.
Conclusion: Our study found that that continuous antibiotic therapy represented only a small proportion of overall 
antibiotic prescribing at our health network. Prolonged courses of antibiotics were used mainly to suppress infections 
thought incurable, but also as primary and secondary prophylaxis and as anti-inflammatory agents. More research is 
needed to understand the impact of long-term antibiotic consumption on both patients and microbial ecology.
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Background
Antibiotics have revolutionised the treatment of acute 
infection, including making many previously life-threat-
ening diseases potentially survivable. With the discovery 
of penicillin [1], and the rapid development of antibiotics 
in the second half of the twentieth century, morbidity and 
mortality associated with bacterial diseases has signifi-
cantly fallen [2]. Antibiotic agents are usually prescribed 
for acute infection. Although there are very few studies of 
efficacy, long term antibiotics are used for three distinct 
purposes; prophylaxis (primary or secondary), long term 
suppression of existing infections and for non-antibiotic 
effects like immunomodulation, or prokinetic effects 
[3–12].
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With the rise of the use of antibiotics in humans and 
agriculture, has come the increasing scourge of antibiotic 
resistance [13, 14]. In principle, long-term antimicrobial 
use might play a role in the development of resistance. 
This population of patients has not been well studied, and 
it is not known what proportion of overall antimicrobial 
prescribing is intended to be for long-term courses. We 
wished to examine the number of patients on long-term 
antibiotics, review their indications, and to see if they 
might be so large a proportion as to play a role in the 
development of antibiotic resistance.
The aim of this analysis was to describe the use of long-
term antibiotics in hospital outpatients, and to determine 
how many patients were on long-term suppressive anti-
biotic therapy. An analysis of these patients including 
indication (medical condition, microbiology) and anti-
microbial agent and dose, was performed, to describe in 
detail this previously unstudied, yet important popula-
tion of patients.
Methods
A retrospective, cross-sectional study was performed 
of the dispensing episodes of antimicrobial agents at 
Monash Health, an integrated health network in Mel-
bourne, Victoria, Australia, which comprises 6 public 
hospitals with 2130 acute, sub-acute, mental health and 
aged care beds, 19 community health service centres and 
residential care facilities, In 2013–14, 843,162 patients 
received care as outpatients at specialty clinics including 
endocrinology, neurosurgery, rheumatology, renal trans-
plant and orthopaedics [15].
Eligible patients were identified using the hospital drug 
management system (Merlin Ver. 4.94, Pharmhos Soft-
ware, Port Melbourne, Victoria, Australia). All outpatient 
prescriptions of antimicrobial agents over a 6  month 
period (February–July 2014) were extracted and this data 
was entered in Microsoft Excel (Microsoft Corp, Seattle 
WA, 2015). The dispensing records were filtered for those 
with at least one repeat, oral formulations (including 
tablets, capsules and granules), and antibacterial agents 
(using the WHO Collaborating Centre for Drug Statistics 
ATC classification system). Inpatient prescriptions, intra-
venous orders, topical or non-oral formulations were 
excluded. Patients were identified who were prescribed 
antibacterial agents with an intended duration of 1 year 
or greater. Medical records were reviewed to determine 
patient demographics, the indications for prescription 
including microbiology, the intended duration, and the 
prescribing doctor specialty. A descriptive analysis was 
performed on this data.
Ethics approval was granted for the project by the 
Monash Health Human Research Ethics Committee, and 
individual patient consent was not required for this ret-
rospective study.
Results
Of a total of 66,127 outpatient prescriptions, 514 
patients were prescribed one or more oral antibacterial 
agents, and 202 outpatients fulfilled our study criteria, 
identified treated with an intended duration of 1 year or 
greater.
Three distinct indications for prolonged antibiotic ther-
apy were identified: primary prophylaxis in the context 
of immunosuppression, secondary prophylaxis for infec-
tions thought incurable, and long-term antibiotics for 
“other” reasons (see below).
Sixty-nine (34%) of the 202 patients were prescribed 
prolonged antibiotic courses for primary prophylaxis 
for Pneumocystis jirovecii pneumonia (PJP), and post 
splenectomy. PJP prophylaxis with trimethoprim/sul-
famethoxazole was prescribed in the context of immu-
nosuppression by various specialties including Renal 
Transplant (n  =  1), Haematology (n  =  12), Oncology 
(n = 41), Rheumatology (n = 1), and Infectious Diseases 
(n = 9). Five patients were prescribed antibiotics for sple-
nectomy prophylaxis: amoxicillin (2), erythromycin (1), 
phenoxymethylpenicillin (1), and roxithromycin (1).
Of the 202 patients prescribed prolonged antibiotic 
courses, 43 (21%) were for long-term suppressive therapy, 
with over half (n  =  25) for infected prosthetic devices 
(e.g. joint replacements, spinal fixation devices), and 
also chronic bone infections without prosthetic mate-
rial (n = 6), vascular graft infections (n = 6) and infected 
cardiac devices (n = 6). Antibiotic agents commonly pre-
scribed were rifampicin, in combination with fusidic acid, 
amoxicillin, and phenoxymethylpenicillin. Combination 













Combinaon of 2 or more
agents
Fig. 1 The most commonly prescribed antibiotics for the purpose of 
suppressing incurable infections
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These antibiotics were predominantly prescribed by 
Infectious Diseases doctors (n  =  34), but also by clini-
cians from Cardiology (n  =  1), Rheumatology (n  =  1), 
General Medicine (n = 4) and Orthopaedics (n = 1). In 
all the cases where patients were prescribed antibiot-
ics by other units, Infectious Diseases doctors had been 
consulted for at least the initial prescription. The most 
common organism isolated was methicillin-resistant 
Staphylococcus aureus (MRSA) (n  =  22, 54%). Other 
organisms included methicillin susceptible S. aureus 
(MSSA) (n = 4), coagulase-negative staphylococci, strep-
tococci and Propionibacterium acnes. Eight patients 
were prescribed treatment for infections where multiple 
organisms had been isolated.
The “other” group consisted of patients prescribed pro-
longed antibiotics for difficult to treat infections (with 
a curative intent), such as mycobacterial infections. 
Patients prescribed antimicrobial agents for anti-inflam-
matory purposes, and patients prescribed secondary 
prophylaxis for urinary tract infections (n = 5).
66/202 (33%) patients with cystic fibrosis were pre-
scribed prolonged courses of macrolides or fluo-
roquinolones by respiratory physicians. A planned 
duration was not documented for 63 of 66 (95%) of 
patients. 20/202 (10%) patients with cystic fibrosis were 
prescribed prolonged antibiotic therapy for complex 
mycobacterial infection, including Mycobacterium tuber-
culosis (n =  8), Mycobacterium avium complex (n =  8), 
Mycobacterium leprae (n = 2), Mycobacterium abscessus 
(n = 1) and Mycobacterium haemophilum (n = 1).
Table  1 describes the patient demographics in each 
of the patient groups where antibiotics are used for pri-
mary or secondary prophylaxis. Compared to the other 
indications for prolonged antibiotics, patients with pros-
thetic device-associated infections (including orthopae-
dic prostheses, cardiac devices and vascular grafts) were 
older than patients on prolonged prophylaxis. Infectious 
Diseases consultation was also sought more often in these 
groups.
Discussion
We reviewed 66,127 prescriptions dispensed from our 
health network over a 6  month period, and identified 
202 patients prescribed long-term antibiotics, defined as 
continuous usage of over 1 year. Prolonged courses were 
prescribed in the setting of primary prophylaxis, second-
ary prophylaxis in infections thought incurable, and in 
complex or difficult to treat infections. There were also 
a number of cystic fibrosis patients who were prescribed 
long-term macrolides or fluoroquinolones for anti-
inflammatory rather than anti-infective purposes.
This is the first study to review the long-term antibiotic 
prescribing practices in a tertiary healthcare network. 
With this data we have been able to identify the clini-
cians who prescribed long-term antibiotics courses, and 
for which indications. Infectious diseases doctors did not 
prescribe the majority of courses of prolonged antibiotics 
seen in our review, and a planned duration was often not 
documented.
We have also described the population of patients con-
suming these antibiotics, including their demograph-
ics, and the microorganisms that the antibiotics were 
targeting.
However, our retrospective study, using administrative 
data sets, may have underestimated use of antibiotics in 
some populations. For example, we only identified one 
patient under prescribed trimethoprim-sulphamethox-
azole prophylaxis by our renal transplant unit. We had 
anticipated a higher number of prescriptions for PJP 
prophylaxis post solid organ transplant as per local and 
international guidelines [4, 16, 17]. On review of the renal 
unit prescribing practices, it was noted that prescriptions 
of only 10 tablets with 1 repeat were dispensed to ensure 
frequent follow up, and hence these patients were missed 
by our study methods.
Only four patients were prescribed flucloxacillin or 
cephalexin for long-term suppression of infections with 
methicillin sensitive S. aureus, a common cause of ortho-
paedic and other infections treated at our healthcare net-
work [18]. These antibacterial agents are more likely to be 
prescribed by primary care clinicians and/or dispensed 
by community pharmacies via the Australian Pharmaceu-
tical Benefits Scheme (PBS). The common prescription of 
rifampicin for treatment of chronic MRSA infection can 
be explained by the lack of availability for subsidised pre-
scribing of this expensive agent in the community for this 
indication.
No patients were prescribed prolonged or prophylac-
tic courses of antibiotics for recurrent chest infections 
Table 1 Patient Demographics by indication for prolonged 
antibiotic therapy
PJP, Pneumocystis jirovecii pneumonia; SD, standard deviation
Indication (number) Age Gender Infectious diseases
Median (SD) Male (%) Consultation (%)
Splenectomy (5) 26 (21) 3 (60) 1 (20)
PJP prophylaxis (69) 16 (25.1) 35 (55) 9 (14)
Prosthetic device infec-
tion (25)
77 (9.6) 13 (52) 23 (92)
Vascular graft infection 
(6)
81.5 (7.5) 3 (50) 5 (83)
Osteomyelitis/septic 
arthritis (6)
65.5 (3.7) 4 (67) 4 (67)
Implantable cardiac 
device (6)
65 (19.4) 3 (60) 3 (50)
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which is not recommended in evidence based guidelines 
[8, 19, 20]. Clinicians may be prescribing these antibiotics 
outside of the public hospital outpatient setting (i.e. pri-
vate consulting rooms) and/or dispensed in community 
pharmacies.
The proportion of patients on long-term antibiotics 
relative to the total number of dispensed prescriptions 
was low, reflecting a very small number of patients tak-
ing antibiotics for a year or longer. We anticipate that 
this population may not be important in overall antibi-
otic usage and the development of antimicrobial resist-
ance. However while our review has defined this group 
of patients, little has been studied about the long-term 
effects of taking prolonged courses of antibiotics, from 
side effect burden, to alteration of the microbiome on 
an individual and population level. Further studies are 
needed to explore these gaps in knowledge.
Conclusion
The heterogeneity in indications and antibiotics pre-
scribed highlights the lack clear guidelines based on 
well-designed randomised controlled trials, particularly 
relating to suppression of infections thought incurable. 
More research is needed to understand the impact, on an 
individual and population level, of long-term antibiotic 
consumption, in order to design appropriate guidelines 
for the prescribing and monitoring of life-long antibiotic 
therapy.
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